Disclosures for "A Phase 2 Study of ATH434, a Novel Inhibitor of α-synuclein Aggregation, for the Treatment of Multiple System Atrophy (MSA)"
-
Dr. Stamler has received personal compensation for serving as an employee of Alterity Therapeutics.
-
Cynthia Wong has received personal compensation for serving as an employee of Alterity Therapeutics.
-
Paula Trujillo Diaz has nothing to disclose.
-
Margaret Bradbury has received personal compensation for serving as an employee of Alterity Therapeutics. The institution of Margaret Bradbury has received research support from Alterity Therapeutics.
-
Ms. Lucas has received personal compensation for serving as an employee of Advanced Clinical - on assignment at Alterity Therapeutics.
-
Dr. Claassen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Neuroscience. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark . The institution of Dr. Claassen has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alterity. Dr. Claassen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva Neuroscience. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for HD Insights. The institution of Dr. Claassen has received research support from NIH. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from HDSA. The institution of Dr. Claassen has received research support from Department of Defense. The institution of Dr. Claassen has received research support from Griffin Family Foundation. The institution of Dr. Claassen has received research support from Neurocrine. The institution of Dr. Claassen has received research support from Vaccinex. The institution of Dr. Claassen has received research support from AbbVie. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from Genentech/ Roche. The institution of Dr. Claassen has received research support from Prilenia. The institution of Dr. Claassen has received research support from Neurocrine/ HSG.